Dr. Metwalli is a urologic oncologist trained in robotic surgery and specializing in cancers of the kidney, prostate, bladder, penis, and testis. Dr. Metwalli completed a urology oncology fellowship from UT MD Anderson and the Urologic Oncology Branch of the National Cancer Institute, NIH. Dr. Metwalli spent 4 1/2 years as the Chief of Urology at Howard University Hospital (HUH) in the Spring of 2018. During that time, he established a robotic surgery program and was the Director of Robotic Surgery for HUH. In that role, he oversaw the expansion of robotic surgery in to 5 different service lines and designed a robotic surgery education curriculum for general surgery residents. He also expanded the urology faculty and prepared the Division of Urology to resume the urology residency program which was disbanded in 2003-4. He successfully completed the Harvard Macy Institute Program for Health Educators and completely overhauled the medical school curriculum for the rotating medical students from Howard University College of Medicine (HUCM). As the Director of Urologic Oncology in the Howard University Cancer Center (HUCC), Dr. Metwalli successfully applied for a DOD funded Concept Award Grant to investigate the genetic basis of papillary kidney cancer in African American subjects. In addition, after more than a decade of not matching any HUCM students in urology, during Dr. Metwalli's tenure six HUCM students successfully matched in urology. Prior to his time at HUH, Dr. Metwalli spent 7 1/2 years as the primary kidney cancer surgeon at the Urologic Oncology Branch (UOB) of the National Cancer Institute in the National Institutes of Health (NIH). During that time he trained urologic oncology fellows and urology residents and spearheaded the conversion of multiplex partial nephrectomies from predominantly open surgical approaches to minimally invasive and robotic surgeries. Prior to joining the NIH, Dr. Metwalli spent 3 years in private practice as the only fellowship trained urologic oncologist in a large urology group in Baltimore, Maryland. During his time with the Urologic Oncology Branch, Dr. Metwalli developed a national and international reputation and has been asked to speak on the surgical management of urologic cancers across the country and around the world. Dr. Metwalli has published over 80 research manuscripts in peer-reviewed journals and has contributed to dozens more as a participant in the Cancer Genome Atlas Research Network. While at NIH, Dr. Metwalli was actively involved in clinical trials research; he was the principal Investigator for a Phase II clinical trial evaluating a novel small molecule radiotracer in patients with clear cell kidney cancer and has been an associate investigator on several other trials.